PLUR (Pluri Inc) צמיחת רווחים בשנה הנוכחית
Pluri Inc. develops cellular therapies to combat metabolic pathologies. The annual growth of net income per share as a percentage reflects the company's dynamics, with the latest value recorded as 0.00. The business relies on robust cold chain logistics, overcoming fierce competition from pharma behemoths. Meanwhile, the operational footprint remains minimal due to strict compliance with bio-waste disposal standards.
פילוחי מדדים פיננסיים ומדדי שוק עבור pluri-biotech.com (PLUR)
Business operational efficiency is determined by the ability to generate net income per share. This metric measures the annual EPS trend, reflecting margin growth or the effect of share count reduction. For Pluri Inc. (PLUR), this trend confirms the commercialization of 3D bioreactors and the scaling of cell technologies. By analyzing the relative EPS growth over 12 months, an investor assesses the actual expansion of the business.
